로딩 중…
지수 로딩 중…
Biotoxtech Co., Ltd.
086040· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,215-9.41%
2026-06-19
Price Chart
Biotoxtech Co., Ltd.-26.78%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 35.35B KRW |
| Revenue | 47.64B KRW |
| Net Income | -3.06B KRW |
| Total Assets | 130.06B KRW |
| Net Assets | 29.25B KRW |
| Employees | 230 |
| Value | |
| P/B | 1.21x |
| P/S | 0.74x |
| FCF Yield | 12.77% |
| Profitability | |
| ROE | -10.46% |
| ROA | -2.35% |
| Op. Margin | -1.05% |
| Revenue Growth | 5.51% |
| Financial Health | |
| Debt Ratio | 444.69% |
| Total Debt | 36.45B KRW |
| FCF | 4.52B KRW |
| Cash | 15.52B KRW |
| Current Ratio | 0.53x |
| Performance | |
| 1Y Return | -26.78% |
| 1M Return | -24.27% |
| From 52W High | -46.17% |
| 1Y MDD | -43.57% |
| Trading | |
| Volume | 37,471 shares |
| Foreign Own. | 1.96% |
| Per Share | |
| EPS | 48 KRW |
| BPS | 2,486 KRW |
Company Info
The company, a non-clinical CRO specialist listed on KOSDAQ in 2007, owns the subsidiary KiforPrime Research. It performs toxicity, safety, and efficacy evaluations for medicines, cell therapies, gene therapies, and chemicals, providing professional contract research services through GLP certification. In line with global industry trends, the company is expanding primate non-clinical trials and pursuing innovation by establishing experimental animal facilities and offering consulting services. Biotoxtech was established in 2000 and is headquartered in Chungcheongbuk-do, Cheongju-si.